Condition

Pulmonary Vascular Disorder

ClinicalTrials.gov condition label

Clinical trials5

Recruiting1

Common interventions8

Lead sponsors shown4

Clinical trials

5 shown

Repurposing Valsartan May Protect Against Pulmonary HypertensionNCT06053580 · 2024-02-28

RECRUITING

Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD)NCT06384534 · 2024-04-01

COMPLETED

HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)NCT06084559 · 2023-07-05

UNKNOWN

Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAHNCT05339087 · 2022-10-24

TERMINATED

Pulmonary Vasculature and Right Heart Dysfunction in Chronic Obstructive Pulmonay DiseaseNCT03184727 · 2017-06-15

UNKNOWN

Common interventions

6-minute walk distance (6MWD) test on ambient airOTHER16-minute walk distance test with supplemental oxygenOTHER1PlaceboDRUG1PlaceboOTHER1Riociguat Oral TabletDRUG1Sham Oxygen therapyOTHER1Supplemental oxygen therapyOTHER1Valsartan 40 mgDRUG1

Leading sponsors

University of Zurich2Chinese Academy of Medical Sciences, Fuwai Hospital1Heidelberg University1University of Washington1

Trial status mix

UNKNOWN2

COMPLETED1

RECRUITING1

TERMINATED1

Phase mix

NA2

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.